Selitop® – launch symposium
Belgrade, 11th December 2019
In Hotel 88 Rooms in Belgrade, in front of more than 80 participants – physicians of different specialties from Belgrade, Valjevo, Šabac, Kragujevac, and Loznica, a professional meeting was held at which the the Vemax Pharma company presented the therapeutic possibilities of the product Selitop®.
This product with a selenium dose of 200 mcg (L-selenmethionine) is widely used, especially in treatments of thyroid diseases. Eminent experts – endocrinologists and ophthalmologists from the Clinical Center of Serbia – delivered lectures on the following topics:
- Selenium and oxidative stress – professor Miloš Žarković, MD, the Clinical Center of Serbia
- Clinical administration of L-selenmethionine in patients with hypothyroidism – assistant professor Biljana Beleslin, MD, the Clinical Center of Serbia
- Clinical administration of L-selenmethionine in patients with hyperthyroidism – professor Jasmina Ćirić, MD, the Clinical Center of Serbia
- Administration of L-selenmethionine in Graves orbitopathy – clinical approach from an ophthalmologist’s standpoint – professor Miroslav Knežević, MD, the Clinical Center of Serbia
A sovereign, guide-confirmed advantage of L-selenmethionine as an organic form of selenium over non-organic forms of selenium is highlighted. This is true for patients with hypothyroidism, but also for those with hypothyroidism and Graves orbitopathy.